Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-Based Treatment Selection in Metastatic Colorectal Cancer
NCT00098787Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Sep 2005
- Primary completion
- Nov 2013
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin, fluorouracil in colorectal cancer (CRC), sponsored by Eastern Cooperative Oncology Group. Started Sep 2005; status: completed.
02
Drugs
bevacizumabirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatinfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00098787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00098787.